Cardiora is a clinical stage pharmaceutical company focused on the development of CRD-102, a new oral medicine for the treatment of end stage heart failure.

Current treatments for end stage heart failure include administration of intravenous inotropes in hospital, but this unfortunately leads to significant healthcare burden, and high hospital re-admission rates for patients who are dependent on inotropes.

Delivered orally, CRD-102 is intended to provide clinicians with additional treatment options for such patients, to ease the symptoms of end stage heart failure, improve quality of life and to reduce hospital re-admission rates in this patient group.